Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2249–2259. doi: 10.1158/1535-7163.MCT-15-0429

Figure 5. Potentiation of effects of AZD6244 by CGM097 against mutant RAS-positive AML cells.

Figure 5

(A) Approximately 3-day treatment of mutant NRAS-expressing OCI-AML3 cells with AZD6244, CGM097, or a combination of both. This study is representative of two independent studies for which similar results were observed. (B) Combination indices calculated for studies in (A). (C) Effects of AZD6244+CGM097 on induction of apoptosis, as compared to either agent alone, against OCI-AML3 cells. Bar graphs shown in “C” are representative of apoptosis data shown in Supplementary Figure 7.